BLOCKBUSTER DRUGS BECOME RIP-OFFS
The unsustainability of the Gates/Fauci Big Pharma model of drug development is now plain for all to see.
It started to sound a bit dodgy when ‘Glybera’, the first gene therapy drug to be launched in Europe, was priced at $1M, and unsurprisingly, was withdrawn from the market having sold diddly-squat, see Goodbye Glybera!…
Keep reading with a 7-day free trial
Subscribe to INSIDE PHARMA to keep reading this post and get 7 days of free access to the full post archives.